Seelos Therapeutics Inc

NASDAQ:SEELUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Contact Information

Headquarters

300 PARK AVENUE, 2ND FLOORNEW YORK, NY, United States 10022

Phone

646-293-2100

Fax

858-436-8155

Executives

Chairman of the Board

Richard Pascoe

President, Chief Executive Officer, Director

Raj Mehra

Chief Financial Officer

Michael Golembiewski

Independent Director

Margaret Dalesandro

Independent Director

Brian Lian